A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

Cited by (384)

Items 101–200 of 384

1. Leveraging deep learning to improve vaccine design
   Andrew P. Hederman, Margaret E. Ackerman · 2023 · Trends in Immunology
2. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses
   Concepción Palomo, Vicente Más, Michelle L. Thom, Mónica Vázquez, Olga Cano, María Carmen Terrón, Daniel Luque, Geraldine Taylor, José Antonio Melero · 2016 · Journal of Virology
3. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
   Alba Torrents de la Peña, Rogier W. Sanders · 2018 · Retrovirology
4. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo
   Yael Bar-Peled, Darren Diaz, Alma Pena-Briseno, Jackelyn Murray, Jiachen Huang, Ralph A. Tripp, Jarrod J. Mousa · 2019 · Journal of Virology
5. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate
   Bo Liang, Joan O. Ngwuta, Sonja R. Surman, Barbora Kabatova, Xiang Liu, Matthias Lingemann, Xueqiao Liu, Lijuan Yang, Richard L. Herbert, Joanna Swerczek et al. · 2017 · Journal of Virology
6. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation
   2024
7. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein
   Jessica A. Flynn, Eberhard Dürr, Ryan Swoyer, Pedro Joel Cejas, Melanie S. Horton, Jennifer D. Galli, Scott A. Cosmi, Amy S. Espeseth, Andrew J. Bett, Lan Zhang · 2016 · PLoS ONE
8. Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
   Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Jan Serroyen, Johannes P. M. Langedijk, Hanneke Schuitemaker, Eiríkur Saeland, Roland C. Zahn · 2020 · npj Vaccines
9. Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age
   Jop Jans, Oliver Wicht, Ivy Widjaja, Inge M. L. Ahout, Ronald de Groot, Teun Guichelaar, Willem Luytjes, Marien Isaäk de Jonge, Cornelis A. M. de Haan, Gerben Ferwerda · 2017 · PLoS ONE
10. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector
    Bo Liang, Joan O. Ngwuta, Richard L. Herbert, Joanna Swerczek, David W. Dorward, Emérito Amaro-Carambot, Natalie Mackow, Barbora Kabatova, Matthias Lingemann, Sonja R. Surman et al. · 2016 · Journal of Virology
11. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
    Nusrat Zahan Rouf, Sumit Biswas, Nawseen Tarannum, Labiba Mustabina Oishee, Mutia Masuka Muna · 2022 · RNA Biology
12. The use of databases, data mining and immunoinformatics in vaccinology: where are we?
    Nagendra R. Hegde, Sulgey Gauthami, Halmuthur. M. Sampath Kumar, Jagadeesh Bayry · 2017 · Expert Opinion on Drug Discovery
13. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization
    Brian G. Pierce, Zhen–Yong Keck, Ruixue Wang, Patrick Lau, Kyle Garagusi, Khadija H. Elkholy, Eric A. Toth, Richard A. Urbanowicz, Johnathan D. Guest, Pragati Agnihotri et al. · 2020 · Journal of Virology
14. Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation
    Liang Yú, Shuai Shao, Xin Yu Li, Zi Xin Zhao, Ning Liu, Zhao Ming Liu, Fu Jie Shen, Hao Zhang, Jun Wei Hou, Xue Feng Zhang et al. · 2024 · Science
15. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
    Jeffrey C. Boyington, Michael Gordon Joyce, Mallika Sastry, Guillaume B. E. Stewart-Jones, Man Chen, Wing‐Pui Kong, Joan O. Ngwuta, Paul V. Thomas, Yaroslav Tsybovsky, Yongping Yang et al. · 2016 · PLoS ONE
16. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection
    Nita Patel, Mike Massare, Jing-Hui Tian, Mimi Guebre‐Xabier, Hanxin Lu, Haixia Zhou, Ernest L. Maynard, Daniel R. Scott, Larry R. Ellingsworth, Gregory M. Glenn et al. · 2019 · Vaccine
17. Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations
    Nadine C. Salisch, Ana Izquierdo Gil, Dominika N. Czapska-Casey, Lars Vorthoren, Jan Serroyen, Jeroen T. B. M. Tolboom, Eiríkur Saeland, Hanneke Schuitemaker, Roland C. Zahn · 2019 · npj Vaccines
18. Sequence-Based Prediction of Metamorphic Behavior in Proteins
    Nanhao Chen, Madhurima Das, Andy LiWang, Lee‐Ping Wang · 2020 · Biophysical Journal
19. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability
    Lan Zhang, Eberhard Dürr, Jennifer D. Galli, Scott A. Cosmi, Pedro Joel Cejas, Bin Luo, Sinoeun Touch, Paul Parmet, Arthur Fridman, Amy S. Espeseth et al. · 2018 · Vaccine
20. Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis
    Farah Elawar, Ahmed K. Oraby, Quinten Kieser, Lionel Dylan Jensen, Tyce N. Culp, Frederick G. West, David Marchant · 2020 · Pharmacology & Therapeutics
21. Generation of antigen-specific paired-chain antibodies using large language models
    Perry T. Wasdin, Nicole V. Johnson, Alexis K. Janke, Sofia Held, Toma M. Marinov, Gwen Jordaan, Rebecca A. Gillespie, Léna Vandenabeele, Fani Pantouli, Olivia C. Powers et al. · 2025 · Cell
22. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation
    Normand Blais, Martin Gagné, Yoshitomo Hamuro, Patrick Rheault, Martine Boyer, Ann‐Muriel Steff, Guy Baudoux, Vincent Dewar, Josée Demers, Jean-Louis Ruelle et al. · 2017 · Journal of Virology
23. Structure-based immunogen design — leading the way to the new age of precision vaccines
    Fabian Sesterhenn, Jaume Bonet, Bruno E. Correia · 2018 · Current Opinion in Structural Biology
24. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses
    Guillaume B. E. Stewart-Jones, Jason Gorman, Li Ou, Baoshan Zhang, Michael Gordon Joyce, Lijuan Yang, Cheng Cheng, Gwo‐Yu Chuang, Kathryn E. Foulds, Wing‐Pui Kong et al. · 2021 · Proceedings of the National Academy of Sciences
25. Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus
    Yi-Zong Lee, Jerome Han, Yi-Nan Zhang, Garrett Ward, Keegan Braz Gomes, Sarah Auclair, Robyn L. Stanfield, Linling He, Ian A. Wilson, Jiang Zhu · 2024 · Nature Communications
26. A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection
    Yanjun Zhang, Zheng Zhou, Shenglin Zhu, Xiangyang Zu, Zonglin Wang, Leike Zhang, Wei Wang, Gengfu Xiao · 2019 · Antiviral Research
27. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses
    Gwo‐Yu Chuang, Yen‐Ting Lai, Jeffrey C. Boyington, Cheng Cheng, Hui Geng, Sandeep Narpala, Reda Rawi, Stephen D. Schmidt, Yaroslav Tsybovsky, Raffaello Verardi et al. · 2020 · Journal of Virology
28. Prefusion stabilization of the Hendra and Langya virus F proteins
    Patrick O. Byrne, Elizabeth G. Blade, Brian E. Fisher, David R. Ambrozak, Ajit R. Ramamohan, Barney S. Graham, Rebecca J. Loomis, Jason S. McLellan · 2024 · Journal of Virology
29. CHO cells for virus-like particle and subunit vaccine manufacturing
    Zalma V. Sanchez-Martinez, Sergio P. Alpuche‐Lazcano, Matthew Stuible, Yves Durocher · 2024 · Vaccine
30. Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents
    Tommaso Felicetti, Chiara Sarnari, Roberta Gaito, Oriana Tabarrini, Giuseppe Manfroni · 2024 · Journal of Medicinal Chemistry
31. Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice
    Yu Zheng, Lijun Bian, Huiting Zhao, Yulan Liu, Jingcai Lu, Dawei Liu, Ke Zhang, Yueshuang Song, Yu-Si Luo, Chunlai Jiang et al. · 2020 · Frontiers in Immunology
32. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus
    Emma Rey-Jurado, Jorge A. Soto, Nicolás M. S. Gálvez, Alexis M. Kalergis · 2017 · Human Vaccines & Immunotherapeutics
33. Profiling of hMPV F-specific antibodies isolated from human memory B cells
    Xiao Xiao, Arthur Fridman, Lu Zhang, Pavlo Pristatsky, Eberhard Dürr, Michael A. Minnier, Aimin Tang, Kara S. Cox, Zhiyun Wen, Renée Moore et al. · 2022 · Nature Communications
34. A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses
    Mark J. G. Bakkers, Freek Cox, Annemart Koornneef, Xiaodi Yu, Daan van Overveld, Lam Le, Ward van den Hoogen, Joost Vaneman, Anne Thoma, Richard Voorzaat et al. · 2024 · Nature Microbiology
35. Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
    Qianqian Li, Huan Li, Zhihua Li, Youchun Wang · 2024 · MedComm
36. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge
    Brian E. Gilbert, Nita Patel, Hanxin Lu, Ye Liu, Mimi Guebre‐Xabier, Pedro A. Piedra, Gregory M. Glenn, Larry R. Ellingsworth, Gale Smith · 2018 · Vaccine
37. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes
    Fedechkin, Stanislav O., George, Natasha L., Nuñez Castrejon, Ana M., Dillen, Joshua R., Kauvar, Lawrence M., DuBois, Rebecca M. · 2020 · Journal of Virology
38. Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development
    Henriette Ebel, Tim Benecke, Benjamin Vollmer · 2022 · Viruses
39. Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats
    Christina Joyce, Ciaran D. Scallan, Roberto Mateo, Robert B. Belshe, Sean N. Tucker, Anne Moore · 2018 · Vaccine
40. Moving from Empirical to Rational Vaccine Design in the ‘Omics’ Era
    Mansi Sharma, Florian Krammer, Adolfo García‐Sastre, Shashank Tripathi · 2019 · Vaccines
41. Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity
    Nita Patel, Jing-Hui Tian, Rhonda Flores, Kelsey Jacobson, Michelle Walker, Alyse D. Portnoff, Mimi Gueber-Xabier, Michael J. Massare, Greg M. Glenn, Larry R. Ellingsworth et al. · 2020 · Vaccines
42. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?
    Sofie Schaerlaekens, Lotte Jacobs, Kim Stobbelaar, Paul Cos, Peter Delputte · 2024 · Vaccines
43. Respiratory syncytial virus
    Alessandra Pierangeli, Carolina Scagnolari, Guido Antonelli · 2018 · Minerva Pediatrics
44. Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine
    Cameron Bissett, Sandra Belij‐Rammerstorfer, Marta Ulaszewska, Holly Smith, Reshma Kailath, Susan Morris, Claire Powers, Sarah Sebastian, Hannah Sharpe, Elizabeth R. Allen et al. · 2024 · npj Vaccines
45. A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2
    Benjamin Vollmer, Henriette Ebel, Renate Rees, Julia Nentwig, Thomas Mulvaney, Jürgen Schünemann, Jens Krull, Maya Topf, Dirk Görlich, Kay Grünewald · 2025 · Nature
46. Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles
    Charles J. Russell, Eric A. F. Simões, Julia L. Hurwitz · 2018 · Viral Immunology
47. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection
    Sara Taleb, Khalid Alansari, Gheyath K. Nasrallah, Mohamed A. Elrayess, Asmaa A. Al Thani, Alexandrine Derrien-Colemyn, Tracy J. Ruckwardt, Barney S. Graham, Hadi Mohamad Yassine · 2021 · International Journal of Infectious Diseases
48. Respiratory syncytial virus infection in the modern era
    Martin Ludlow · 2023 · Current Opinion in Infectious Diseases
49. The RSV F p27 peptide: current knowledge, important questions
    Wanderson Cabral de Rezende, Hadley E. Neal, Rebecca Dutch, Pedro A. Piedra · 2023 · Frontiers in Microbiology
50. A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion glycoprotein
    Ahmed K. Oraby, Aleksandra Stojic, Farah Elawar, Leanne M. Bilawchuk, Ryley D. McClelland, Kaci Erwin, Madison J. Granoski, Cameron D. Griffiths, Justin D. Frederick, Elena I Arutyunova et al. · 2025 · npj Viruses
51. Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses
    Annie M. Dosey, Daniel Ellis, Seyhan Boyoglu-Barnum, Hubza Syeda, Mason Saunders, Michael J. Watson, John C. Kraft, Minh Nguyet Pham, Miklós Guttman, Kelly K. Lee et al. · 2023 · Cell Reports
52. New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV
    Nicolás M. S. Gálvez, Jorge A. Soto, Alexis M. Kalergis · 2017 · International Journal of Molecular Sciences
53. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
    Harrison C. Bergeron, Ralph A. Tripp · 2021 · Expert Opinion on Investigational Drugs
54. HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
    Brittany L Ober Shepherd, David Chang, Sandhya Vasan, Julie A. Ake, Kayvon Modjarrad · 2022 · Current HIV/AIDS Reports
55. RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
    Freek Cox, Eiríkur Saeland, Anne Thoma, Ward van den Hoogen, Lisanne Tettero, Joke Drijver, Cornelis Vaneman, Yolinda van Polanen, Tina Ritschel, Arangassery Rosemary Bastian et al. · 2023 · Vaccines
56. Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
    Badiaa Bouzya, Ronan Nicolas Rouxel, Lionel Sacconnay, Romuald Mascolo, Laurence Nols, Stéphanie Quique, Loïc François, Anne Atas, Lucile Warter, Nancy Dezutter et al. · 2023 · npj Vaccines
57. Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization
    Annelies Leemans, Marlies Boeren, Winke Van der Gucht, Isabel Pintelon, Kenny Roose, Bert Schepens, Xavier Saelens, Dalan Bailey, Wim Martinet, Guy Caljon et al. · 2018 · Viruses
58. Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly
    Max Beugeling, Jildou De Zee, Herman J. Woerdenbag, Henderik Willem Frijlink, Jan Wilschut, Wouter L.J. Hinrichs · 2019 · Expert Review of Vaccines
59. A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates
    Aneesh Vijayan, Ronald Vogels, Rachel Groppo, Yi Jin, Selina Khan, Mirjam van Kampen, Sytze H.T. Jorritsma, Satish Boedhoe, Miranda R.M. Baert, Harry A. van Diepen et al. · 2024 · Nature Communications
60. Evaluation of the role of respiratory syncytial virus surface glycoproteins F and G on viral stability and replication: implications for future vaccine design
    Darby DeFord, Jenna M. Nosek, Katelyn R. Castiglia, Emily F. Hasik, Megan E. Franke, Benjamin C. Nick, Alyssa M. Abdelnour, Caitlin E. Haas, Nathan A. Junod, Karina N. Latsko et al. · 2019 · Journal of General Virology
61. Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus
    Li Ou, Steven J. Chen, I‐Ting Teng, Lijuan Yang, Baoshan Zhang, Tongqing Zhou, Andrea Biju, Cheng Cheng, Wing‐Pui Kong, Nicholas C. Morano et al. · 2023 · PLoS Pathogens
62. Clinical research on RSV prevention in children and pregnant women: progress and perspectives
    Xuejia Gong, Erdan Luo, Fan Li, Wanggang Zhang, Yan Yang, Yuhua Du, Xiao Yang, Shasha Xing · 2024 · Frontiers in Immunology
63. Flexibility of the Head-Stalk Linker Domain of Paramyxovirus HN Glycoprotein Is Essential for Triggering Virus Fusion
    Emmanuel Adu‐Gyamfi, Lori S. Kim, Theodore S. Jardetzky, Robert A. Lamb · 2016 · Journal of Virology
64. Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain
    Jee-Hyun Lee, Youri Lee, Laura Klenow, Elizabeth M. Coyle, Juanjie Tang, Supriya Ravichandran, Hana Golding, Surender Khurana · 2021 · EMBO Molecular Medicine
65. Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice
    Jin Luo, Huan Qin, Lei Lei, Wange Lou, Ruitong Li, Zishu Pan · 2022 · Frontiers in Immunology
66. Respiratory Syncytial Virus Infection: Treatments and Clinical Management
    Shiza Malik, Tahir Ahmad, Khalid Muhammad, Yasir Waheed · 2023 · Vaccines
67. Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
    Eiríkur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Cornelis Vaneman, Lisanne Tettero, Freek Cox, Jan Serroyen et al. · 2023 · npj Vaccines
68. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope
    Ryan S. McCool, Maryam Mukhamedova, Sabrina M. Bush, Alexandrine Derrien-Colemyn, Cory M. Acreman, Daniel Wrapp, Tracy J. Ruckwardt, Barney S. Graham, John R. Mascola, Jason S. McLellan · 2023 · Journal of Virology
69. Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis
    Yi Pang, Haishan Lu, Demin Cao, Xiaoying Zhu, Qinqin Long, Fengqin Tian, Xi‐Dai Long, Yulei Li · 2024 · BMC Public Health
70. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients
    Xunyan Ye, Obinna P. Iwuchukwu, Vasanthi Avadhanula, Letisha O. Aideyan, Trevor McBride, Laura Ferlic‐Stark, Kirtida D Patel, Felipe-Andrés Piedra, Dimpy P. Shah, Roy F. Chemaly et al. · 2018 · The Journal of Infectious Diseases
71. Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models
    Eiríkur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Cornelis Vaneman, Lisanne Tettero, Jan Serroyen, Hanneke Schuitemaker et al. · 2021 · Vaccine
72. Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein
    Johannes P. M. Langedijk, Freek Cox, Nicole V. Johnson, Daan van Overveld, Lam Le, Ward van den Hoogen, Richard Voorzaat, Roland C. Zahn, Leslie van der Fits, Jarek Juraszek et al. · 2024 · Nature Communications
73. The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion
    Imogen M. Bermingham, Keith J. Chappell, Daniel Watterson, Paul R. Young · 2017 · Journal of Virology
74. A Vulnerable, Membrane-Proximal Site in Human Respiratory Syncytial Virus F Revealed by a Prefusion-Specific Single-Domain Antibody
    Iebe Rossey, Ching‐Lin Hsieh, Koen Sedeyn, Marlies Ballegeer, Bert Schepens, Jason S. McLellan, Xavier Saelens · 2021 · Journal of Virology
75. A general computational design strategy for stabilizing viral class I fusion proteins
    Gonzalez, Karen J., Huang, Jiachen, Criado, Miria F., Banerjee, Avik, Tompkins, Stephen M., Mousa, Jarrod J., Strauch, Eva-Maria · 2024 · Nature Communications
76. Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states
    Momei Zhou, Benjamin Vollmer, Emily A. Machala, Muyuan Chen, Kay Grünewald, Ann M. Arvin, Wah Chiu, Stefan L. Oliver · 2023 · Nature Communications
77. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity
    Lucy Rutten, Maarten Swart, Annemart Koornneef, Pascale Bouchier, Sven Blokland, Ava Sadi, Jarek Juraszek, Aneesh Vijayan, Sonja P. R. Schmit-Tillemans, Johan W. A. Verspuij et al. · 2024 · Scientific Reports
78. Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein
    Lori M. Cullen, Madelyn R. Schmidt, Gretel M. Torres, Adam A. Capoferri, Trudy G. Morrison · 2019 · Vaccines
79. RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera
    Cassandra A. L. Simonich, Teagan E. McMahon, Xiaohui Ju, Timothy C. Yu, Natalie Brunette, Terry Stevens‐Ayers, Michael Boeckh, Neil P. King, Alexander L. Greninger, Jesse D. Bloom · 2025 · Journal of Virology
80. A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein
    Marlies Ballegeer, Revina C. van Scherpenzeel, Teresa Delgado, María Iglesias‐Caballero, Blanca García‐Barreno, Shubham Pandey, Scott A. Rush, Joost A. Kolkman, Vicente Más, Jason S. McLellan et al. · 2023 · mBio
81. Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
    Eduardo Olmedillas, Olga Cano, Isidoro Martínez, Daniel Luque, María Carmen Terrón, Jason S. McLellan, José Antonio Melero, Vicente Más · 2017 · EMBO Molecular Medicine
82. Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients
    Xunyan Ye, Wanderson Cabral de Rezende, Obinna P. Iwuchukwu, Vasanthi Avadhanula, Laura Ferlic‐Stark, Kirtida D. Patel, Felipe-Andrés Piedra, Dimpy P. Shah, Roy F. Chemaly, Pedro A. Piedra · 2020 · Vaccines
83. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3
    Ravendra Garg, Robert M. Brownlie, Laura J. P. Latimer, Volker Gerdts, Andrew A. Potter, Sylvia van Drunen Littel‐van den Hurk · 2018 · Antiviral Research
84. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus
    Jorge C. G. Blanco, Lurds R. Fernando, Wei Zhang, Arash Kamali, Marina S. Boukhvalova, Lori W. McGinnes, Trudy G. Morrison · 2019 · Journal of Virology
85. Vaccine Development for Human Pneumoviruses
    Elhadji Birane Mboup, Marie‐Ève Hamelin, Julia Dubois, Manuel Rosa‐Calatrava, Guy Boivin · 2025 · Vaccines
86. Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F
    Wayne D. Harshbarger, Sai Tian, Newton Wahome, Ankita Balsaraf, Deep S. Bhattacharya, Desheng Jiang, Ratnesh Pandey, Kunal Tungare, Kristian Friedrich, Nurjahan Mehzabeen et al. · 2020 · PLoS Pathogens
87. Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages
    Sonal V. Gidwani, Devarshi Brahmbhatt, Aaron Zomback, Mamie Bassie, Jennifer Martinez, Jian Zhuang, John Schulze, Jason S. McLellan, Roberto Mariani, Peter Alff et al. · 2024 · Nature Communications
88. X-ray Structures of the Post-fusion 6-Helix Bundle of the Human Syncytins and their Functional Implications
    Katinka Ruigrok, M.C. Vaney, Julian Buchrieser, Eduard Baquero, Jan Hellert, Bruno Baron, Patrick England, Olivier Schwartz, Felix Augusto Rey, Marija Backović · 2019 · Journal of Molecular Biology
89. Targeting Viral Surface Proteins through Structure-Based Design
    Yogesh B. Narkhede, Karen J. Gonzalez, Eva‐Maria Strauch · 2021 · Viruses
90. Accelerating protein design by scaling experimental characterization
    Jason Qian, Lukas F. Milles, Basile I. M. Wicky, Robert J. Ragotte, Amir Motmaen, Andrew J. Borst, Rebecca Skotheim, Sebastian Ols, Brian Coventry, Xinting Li et al. · 2026 · Nature Communications
91. Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G
    Richard Voorzaat, Freek Cox, Daan van Overveld, Lam Le, Lisanne Tettero, Joost Vaneman, Mark J. G. Bakkers, Johannes P. M. Langedijk · 2024 · Vaccines
92. Two RSV Platforms for G, F, or G+F Proteins VLPs
    Binh Ha, Jie E Yang, Xuemin Chen, Samadhan J. Jadhao, Elizabeth Wright, Larry J. Anderson · 2020 · Viruses
93. Dynamical Differences in Respiratory Syncytial Virus
    Ryan A. Heumann, Carly Duncan, Christopher C. Stobart, Scott Kaschner · 2021 · Bulletin of Mathematical Biology
94. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention
    Shaoju Qian, Danqiong Zhang, Zishan Yang, Ruixue Li, Xuehan Zhang, Feifei Gao, Lili Yu · 2024 · International Immunopharmacology
95. Progress on Respiratory Syncytial Virus Vaccine Development and Evaluation Methods
    Lie Deng, H. Cao, Guichang Li, Kaiwen Zhou, Zhenming Fu, Jiaying Zhong, Zhongfang Wang, Xiaoyun Yang · 2025 · Vaccines
96. The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent
    Wanderson Cabral de Rezende, Xunyan Ye, Laura S. Angelo, Alexandre F. Carisey, Vasanthi Avadhanula, Pedro A. Piedra · 2023 · Journal of Virology
97. Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F 2 Subunit Are Critical for Its Fusion Activity
    Stephanie N. Hicks, Supranee Chaiwatpongsakorn, Heather M. Costello, Jason S. McLellan, William C. Ray, Mark E. Peeples · 2018 · Journal of Virology
98. Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein
    Qingqing Xie, Zhao Wang, Fengyun Ni, Xiaorui Chen, Jianpeng Ma, Nita Patel, Hanxin Lu, Ye Liu, Jing-Hui Tian, David C. Flyer et al. · 2019 · PLoS ONE
99. Enhanced humoral and CD8 + T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells
    Ying Hua, Yue-Ying Jiao, Yao Ma, Xiang-Lei Peng, Yuan-Hui Fu, Xiujuan Zhang, Yuan-Bo Zheng, Yan-Peng Zheng, Tao Hong, Jinsheng He · 2017 · International Immunopharmacology
100. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles
     Young‐Man Kwon, Youri Lee, Ki Hye Kim, Yu Jin Jung, Zhuo Ya Li, Subbiah Jeeva, Sujin Lee, Martin L. Moore, Sang‐Moo Kang · 2019 · Vaccine